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Abstract: Purpose 
The endogenous or exogenous origin of Staphylococcus aureus, responsible for orthopaedic surgical 
site infections (SSI), remains debated.  
Methods 
We conducted a multicentre prospective cohort study to analyse the respective part of exogenous 
contamination and endogenous self-inoculation by S. aureus during elective orthopaedic surgery. The 
nose of each consecutive patient was sampled before surgery. Strains of S. aureus isolated from the 
nose and the wound, in case of SSI, were compared by antibiotypes or pulsed field gel electrophoresis 
(PFGE).  
Results 
3908 consecutive patients undergoing orthopaedic surgery were included. Seventy seven patients 
developed an SSI (2%), including 22 related to S. aureus (0.6%). S. aureus was isolated from the nose of 
790 patients (20.2%) at the time of surgery. In multivariate analysis, S. aureus nasal carriage was 
found as a risk factor for S. aureus SSI in orthopaedic surgery. However, only 9 subjects exhibiting S. 
aureus SSI had been found carriers before surgery: when compared, 3 pairs of strains were considered 
different and 6 similar.  
Conclusion 
In most cases of S. aureus SSI, either an endogenous origin could not be demonstrated, or pre-operative 
nasal colonisation retrieved a strain different from the one recovered from the surgical site 
 
Response to Reviewers: Reply to reviewers 
 
Thank you for these interesting comments. Please find below our answers to the queries of the two 
reviewers. 
 
 
Reviewer 1 
 
It is unfortunate that they did not screen other sites such as the throat and perineum. 
 
We agree with this comment. Initially, the protocol included a rectal swabbing but many patients were 
reluctant to this proposal. Due to a high rate of missing data during the initial step of the study, we 
decided to stop the sampling of this site. The following sentence was added in the discussion section of 
the new manuscript (page 11; lines 12 to 14): "Our protocol included initially a rectal swabbing before 
surgery; however, since many patients denied this sample, the data regarding rectal specimens could 
not be taken into consideration". Concerning the throat sampling, when the study was designed in 
2002, sampling this site was not recommended since this specimen was not considered at this time to 
increase significantly the sensitivity of the recovery of S. aureus from the upper respiratory tract as 
shown later by Metz et al. in 2007 [ref 23] (this point is discussed page 11, lines 14 to 17). 
 
 
They could point out that sole carriage at these sites is rare (perhaps 10%) and add this to their 
estimates of the possible size of the problem (20% larger!). Nasal carriage rather than carriage should 
be in the text. 
 
We also agree with this comment, which is emphasised in the new discussion section (page 11; lines 14 
to 17): "With a single nasal sample and in the absence of additional throat and rectal specimens, the 
frequency of carriage of S. aureus in our cohort was certainly underestimated, as illustrated by the 
figure of 20.2% of nasal carriers in this study compared to 37.1% in the one of Mertz et al [23] that 
combined nasal and throat samplings." 
 
 
Comment 1 about CNS data: 
1) Table 3 has overall data.  They could compare the antibiograms of the individual isolates and see if 
there are very different strains.  I doubt the organisms are available for molecular analysis (if so this 
could be "future work" for the discussion) but at least the antibiograms could be compared by ward 
and centre and see if there are any similarities and differences and informed guesses made as to the 
likelihood of cross infection e.g. quinolone resistance is  usually mutational 
2) All the other infected organism data.  Again what about antibiograms and possible cross infection? 
 
The goal of the study was to address the potential link between S. aureus nasal carriage and occurrence 
of S. aureus SSI, and not to study CNS or other bacterial cross infections. Strains other than S. aureus 
were not kept for further analysis. By contrast, the potentiality of cross infections with S. aureus was 
investigated and presented with some details in the revised manuscript (see below). 
 
 
3) S aureus data. 
We need to see their rule set for deciding why the extra 5 strains were different or similar. This is a 
difficult area and must be explained. 
 
The way used to compare antibiotypes is reported in the method section (page 6, lines 12 to 16). As 
required by the referee, additional information regarding the comparison of antibiotic profiles has 
been added in the footnotes of Table III. 
 
 
They should compare the 13 SA from non carriers (and indeed the carriers) to see if there are possible 
issues of cross infection in terms of time person and place of the affected patients.  Are these strains 
similar by PFGE?  Are they similar to any of the carriers? 
 
From the 13 S. aureus SSI strains isolated from non nasal carriers, 8 were available for comparison by 
PFGE: all these strains exhibited independent profiles, also different from those of strains isolated from 
the nose of colonised patients. The 5 remaining strains were isolated from non nasal carriers 
hospitalized in 5 different centres, excluding cross transmission. These data were added in the result 
section page 9 lines 10 to 13. 
 
 
Table IV only has death related risk analysis not as stated on page 10 lines 23-24 for SSI and SA nasal 
carriage. 
 
Because of the low number of SSI infections, the multivariate analysis was run with a maximum of 3 
covariates selected among the most significant in the univariate analyses. This sentence was added in 
the method section (page 8 lines 8 to 10). We also modified the sentence presenting Table IV (page 10 
lines 14 to 15). 
 
 
4) There are also the therapeutic issues raised by the AST results for all categories of infections above.  
These are perhaps a little peripheral but I think it would add to the paper or perhaps be another one if 
there are clinical outcome data? 
 
Data regarding therapeutic issues are not presented in this paper. Another clinical paper focusing on 
these results is in preparation 
 
 
Other points 
How were nasal swabs taken: were the swabs moistened? 
 
The precision regarding moistened transport medium was added in the method section (page 5, line 1). 
 
 
Was the PFGE protocol validated to be able to distinguish strains and how?  
 
The criteria for PFGE interpretation are described page 6 lines 10 to 12 "For a same patient, according 
to Tenover's criteria [18], two S. aureus strains were classified as epidemiologically distinct if a 
difference of more than three bands was ascertained between the PFGE profiles performed in a same 
run". 
 
 
Reviewer 2 
 
First this was a multicenter study and in these kind of studies cluster effects may occur. In the 
multivariate analysis, adjustment for cluster effects was not included. This would strengthen the 
conclusions. 
 
As pointed by the reviewer it is important to look for cluster effect. This was investigated by adding a 
"centre" variable in the different statistical analyses. This variable did not remain in the final model 
used for multivariate analysis. But as required by the referee, we performed another multivariate 
analysis using windows SAS® 9.1 software to adjust for cluster effect. This was added in the method 
section (page 7, line 25). We replaced the results of the previous multivariate analysis performed using 
SPSS software by the results of this multivariate analysis adjusted for cluster effect (Table IV). 
 
 
Second, the authors conclude that the majority of the S. aureus strains are of exogenous origin. They 
put it quite strong in the conclusions that 'at least 16 were not endogenous'. In my opinion this is not 
correct. The nasal cultures were negative but this may have been a false-negative result, e.g. due to the 
sampling technique. As the carriage rate was only 20% it is clear that the culture technique was not 
very sensitive (normally 30% of the population is nasal carrier). Therefore, I suggest to modify this 
conclusion.  
In the majority of cases an endogenous origin could not be demonstrated would be more correct.  
 
We agree with this comment. The discussion section was amended accordingly (see answer to 
reviewer 1 and additional sentence in page 11; lines 14 to 17)). 
As suggested by the referee, we also modified the conclusion; the sentence "In most cases of S. aureus 
SSI, pre-operative nasal colonization was not documented or retrieved a different strain from the 
infecting pathogen" was replaced by the following one in the new manuscript (page 12, lines 20 to 22 
and in the abstract): "In most cases of S. aureus SSI, either an endogenous origin could not be 
demonstrated, or pre-operative nasal colonisation retrieved a strain different from the one recovered 
from the surgical site" 
 
 
Also, it would be important to provide information on the typing of the strains from non-carriers as 
well. I wonder whether there were many similar strains within centers suggesting a common source? 
 
This point was also addressed by reviewer 1. No cross transmission of S. aureus was documented in 
this cohort. This important point was added in the result and discussion section, page 9 lines 10 to 13. 
The following sentence was added page 12 line 11 to 12 "It is noteworthy that, in our study, no cross 
transmission of S. aureus within centres was documented". 
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* 2 suspicions of prosthesis infection, 4 other foreign materials, 2 canceled surgeries, 1 other 
surgery, 1 hip prosthesis luxation, 1 without clinical data. The remaining patients had no nasal 
sampling 
** no clinical data (n=18) or no nasal sampling (n=41) 
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 2 
Abstract 1 
Purpose 2 
The endogenous or exogenous origin of Staphylococcus aureus, responsible for orthopaedic 3 
surgical site infections (SSI), remains debated.  4 
Methods 5 
We conducted a multicentre prospective cohort study to analyse the respective part of 6 
exogenous contamination and endogenous self-inoculation by S. aureus during elective 7 
orthopaedic surgery. The nose of each consecutive patient was sampled before surgery. 8 
Strains of S. aureus isolated from the nose and the wound, in case of SSI, were compared by 9 
antibiotypes or pulsed field gel electrophoresis (PFGE).  10 
Results 11 
3908 consecutive patients undergoing orthopaedic surgery were included. Seventy seven 12 
patients developed an SSI (2%), including 22 related to S. aureus (0.6%). S. aureus was 13 
isolated from the nose of 790 patients (20.2%) at the time of surgery. In multivariate analysis, 14 
S. aureus nasal carriage was found as a risk factor for S. aureus SSI in orthopaedic surgery. 15 
However, only 9 subjects exhibiting S. aureus SSI had been found carriers before surgery: 16 
when compared, 3 pairs of strains were considered different and 6 similar.  17 
Conclusion 18 
In most cases of S. aureus SSI, either an endogenous origin could not be demonstrated, or 19 
pre-operative nasal colonisation retrieved a strain different from the one recovered from the 20 
surgical site 21 
Keywords. Staphylococcus aureus; nasal carriage; carrier; surgical site infection; hospital 22 
infection; orthopaedic surgery 23 
Trial registration. National Project of Hospital Clinical Research (PHRC) “DEPISTAPH” 24 
Ministère de la Santé   France. 25 
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 3 
Introduction 1 
 2 
The risk of prosthetic joint infection is less than 2 percent after joint replacement [1-3] or after 3 
implantation of internal fracture-fixation devices [4]. However, the large number of such 4 
procedures performed annually makes these infections highly significant in terms of 5 
mortality, morbidity and costs, as far as the elderly population is increasing in industrialized 6 
countries [5-7]. It is a well-known fact that S. aureus carriage predisposes to post-operative 7 
staphylococcal infection in general surgery [8], in heart surgery [9-10], as in orthopaedic 8 
surgery [11]. However, Kalmeijer et al. [11], in orthopaedic surgery, realized their study in 9 
only one centre, with a limited number of patients. Moreover, the studies showing a 10 
substantial reduction of SSI among patients receiving mupirocin were all compared to 11 
historical control [8, 12-14], whilst Kalmeijer et al.[15], in a double-blind, randomised, 12 
placebo-controlled study, in orthopaedic surgery, failed to show any beneficial effect. So, the 13 
exogenous pathway of contamination in orthopaedic surgery remains an important hypothesis 14 
and we undertook a large prospective multicenter cohort study, to determine whether the nasal 15 
carriage of S. aureus is the main pathway responsible for infection in orthopaedic SSI. 16 
 17 
Patients and methods 18 
 19 
We conducted a prospective epidemiological multicentre observational study to estimate the 20 
relative part of subjects with S. aureus nasal carriage in patients with SSI following prosthetic 21 
and internal fracture-fixation device surgery, and in non-infected patients. We compared, in 22 
SSI patients, the strains of S. aureus colonizing the anterior nares and that isolated from the 23 
site of infection. 24 
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 4 
Patients. All consecutive patients undergoing scheduled orthopaedic surgery with 1 
implantation of prosthesis or internal fracture-fixation device, in seventeen centres (see 2 
appendix), were included from June 2003 to January 2007.  A control visit was performed by 3 
the surgeon at least one month and one year after surgery. Exclusion criteria were non-4 
programmed surgery and suspicion of infection at the site of surgery.   5 
A written informed consent was obtained for all patients. The study protocol was approved by 6 
the regional ethical research committee (Comité de Protection des Personnes Rhône-Alpes I).  7 
The preparation of patients’ skin included at least one preoperative shower with a soap 8 
containing either chlorhexidine or polyvidone iodine, cleansing of the skin with an antiseptic 9 
soap followed by a disinfection with an alcoholic antiseptic in the operative theatre. Antibiotic 10 
prophylaxis was done with cefazolin, 2 grams at the anaesthetic induction. Mupirocin nasal 11 
decontamination was not used whatever the results of the sampling. 12 
One to three months before surgery, the study was explained to the patient during surgical 13 
consultation. Written information was delivered. The nose of the patient was sampled at the 14 
admission. To ensure performance and reproducibility of the nasal sampling, nurses were 15 
trained and a written protocol was available in each participating unit. The patient’s 16 
practitioner was informed of the study and asked to refer the patient to the surgeon if a SSI 17 
was suspected. In the latter case, at least 3 bacteriological samples were taken at the site of the 18 
suspected infection either per-operatively (without antimicrobial prophylaxis) or by aseptic 19 
aspiration using ultrasound guidance. Direct examination and bacteriological culture were 20 
systematically performed.  21 
 22 
Bacteriological methods 23 
Nasal cultures: One swab was used to sample both nares and plated onto sheep blood agar 24 
plate or onto specific S. aureus Chromastaph medium (Biomérieux, Marcy l’Etoile, France) 25 
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 5 
within 24 hours after sampling if a moistened transport medium was used (Transtube®, 1 
Medical Wire and Equipment Co., Corsham, England or Amies agar gel, Copan, Brescia, 2 
Italy) or within 2 hours in the opposite case. Plates were incubated up to 48h at 36°C. The 3 
identification of S. aureus isolates and their sensitivity to antibiotics were determined by 4 
standard microbiological procedures.  5 
As for nasal samples, swabs were cultured within 2 hours after sampling if no transport 6 
medium was used, and within 24 hours in the opposite case. Fluid samples were examined by 7 
light microscopy after Gram staining. They were cultured both aerobically and anaerobically 8 
into blood culture bottles and monitored in an automated system. Solid samples were 9 
dissected into tiny pieces with a lancet in a safety cabinet and then ground down. The 10 
homogenate was cultured onto aerobic and anaerobic media. The media were incubated at 11 
36°C for at least 48 hours for plate cultures and 15 days for liquid broths.  12 
In addition to phenotypic characteristics, all the available couples of strains of S. aureus 13 
isolated from the nose and the infected surgical site were compared by PFGE using SmaI. The 14 
available strains were centralised in a single laboratory where PFGE was performed. Plugs 15 
containing DNA were prepared following a rapid lysis procedure [16]. Bacterial cells from an 16 
overnight broth culture were mixed with 1.6% of SeaPlaque agarose (Cambrex, Rockland, 17 
USA). The plugs were incubated in lysis buffer containing 250 IU of  lysostaphin (AMBI Inc, 18 
Lawrence, NY, USA) for 2 hours at 37°C, followed by a one-hour incubation at 50°C with 19 
ESP buffer containing 100 mg/L of proteinase K. Plugs were rinsed with TE buffer, incubated 20 
in TE with PMFS  for 30 min at 37°C before final washing in TE buffer. The genomic DNA 21 
inserts were digested at 25°C for 2 h with 20 UI of  SmaI enzyme. The fragments were 22 
separated by PFGE with a CHEF-DrII apparatus (Biorad, Ivry sur Seine, France) in a 1.1% 23 
agarose gel (Gigaphor, Promega, Les Ullis, France) in TBE buffer, at 14°C under a field 24 
strength of 6 V/cm and a linear ramp of 1s- 28s for 21 hours.  25 
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 6 
Definitions 1 
Nasal carriage of S. aureus: 2 
Carriage was considered if a strain of S. aureus was recovered at one sampling. Patients 3 
without documented S. aureus carriage were classified non carriers.  4 
SSI: 5 
Definitions for SSI were those edited by the Centers for Disease Control (CDC) [17].  6 
 7 
Classification of pairs of S. aureus strains isolated from the nose and the SSI in a same 8 
patient 9 
For a same patient, according to Tenover’s criteria [18], two S. aureus strains were classified 10 
as epidemiologically distinct if a difference of more than three bands was ascertained between 11 
the PFGE profiles performed in a same run. When the S. aureus strain isolated from the 12 
surgical site was not available for typing, the antimicrobial patterns were used to compare the 13 
strains isolated in a same patient: a difference in antimicrobial susceptibility of two or more 14 
molecules signed different strains; in case of difference concerning one or no antibiotic, 15 
strains were considered phenotypically similar.  16 
 17 
Data recorded 18 
The following variables were recorded for each patient: age, sex, Body Mass Index (BMI), 19 
tobacco use, underlying diseases (malignancy, diabetes, malnutrition, immunodeficiency, 20 
renal deficiency), medications (particularly antibiotics one month before surgery and 21 
immunosuppressive drugs as corticosteroids), rheumatoid arthritis,  kind of procedure 22 
performed and type of prosthesis, cement use, antimicrobial prophylaxis, date of the 23 
admission to the hospital, date of surgery, date of discharge, dates of follow-up, class of 24 
wound contamination, American Society of Anaesthesiologist (ASA) score, duration of 25 
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 7 
surgery, prosthesis first implantation or revision, blood transfusion, hematologic diseases and 1 
notable blood collection after surgery. The data of nasal samplings and their results were also 2 
recorded. In case of SSI, the following data were collected: date of infection, localization of 3 
infection (superficial or deep), clinical symptoms, microbiological identification and 4 
treatment. 5 
 6 
Outcomes 7 
The primary outcome was to identify risk factors of SSI due to S. aureus by using 8 
multivariate analysis with special emphasis to the variable "nasal carriage of S. aureus". The 9 
secondary outcomes were (i) to evaluate the proportion of S. aureus strains isolated in a same 10 
patient from the nose and SSI found similar by microbiological methods, (ii) to estimate the 11 
frequency of S. aureus nasal carriage in our cohort of patients, and (iii) to estimate the risk of 12 
S. aureus SSI. 13 
 14 
Statistical analyses 15 
We estimated that SSI would occur in 1% of hip prosthesis surgery and in 2% of  knee 16 
prosthesis surgery and that the proportion of S. aureus responsible for infection would be 40 17 
%. Overall, we calculated that 4200 patients were needed for this study to detect a 20% 18 
difference of S. aureus nasal carriage between patients without and with SSI due to S. aureus, 19 
given a two-tailed alpha level of 5% and a statistical power of 80%. It was hypothesized that 20 
an attending number of 40 SSI due to S. aureus would give sufficient discriminative power to 21 
compare pairs of strains (nose and SSI) by molecular techniques. 22 
The software used for the collection of the recorded data was Epi-info, version 6.04d Fr 23 
(CDC-WHO).  The SPSS software, version 16.0 (Chicago, Illinois, USA) was used for 24 
univariate and multivariate analyses. Windows SAS® 9.1 software was used to adjust for 25 
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 8 
cluster effect in the multivariate analysis. The rates of SSI and SSI due to S. aureus were 1 
calculated globally and according to patients’ nasal carriage of S. aureus and to the type of 2 
device implemented. These rates were also stratified according to the NNIS index.  3 
Fisher’s exact test was used for analysis of categorical variables. The Wilcoxon non 4 
parametric test was used for mean comparisons. Two multivariate analyses were carried out to 5 
evaluate (i) risk factors for SSI and (ii) risk factors for SSI due to S. aureus. To adjust for 6 
confounding factors, variables with a P value below the 0.05 significance level in univariate 7 
analysis were entered into a multiple logistic regression model. Because of the low number of 8 
SSI infections, the multivariate analysis was run with a maximum of 3 covariates selected 9 
among the most significant in the univariate analyses. P values below the 5% level were 10 
considered statistically significant. 11 
 12 
Results 13 
 14 
Demographic and clinical data 15 
The total duration of the study was 4 years (3 years of inclusion and one year of 16 
supplementary follow-up; end at January 2008). Four thousand and forty-six patients were 17 
included and 3908 (96.6%) patients were evaluated. Demographic characteristics of the 18 
patients are shown in Table I. The causes for exclusion (138 patients) are described in Figure 19 
1. Seventy-seven patients (2%) were considered as victims of SSI. The overall infection rate 20 
was 2.2% for total hip replacement, 1.7% for knee replacement and 1.6% for partial prosthesis 21 
and fracture-fixation devices.  22 
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 9 
Microbiological data 1 
The most common infecting micro-organisms were coagulase-negative Staphylococcus spp. 2 
[0.9% of patients], followed by Staphylococcus aureus [0.6%], and Gram negative bacteria 3 
[0.4%]. Of these infections, 61% arose in the first three months following surgery. There was 4 
no significant change in the infection rate or type of infecting micro-organism over the course 5 
of the study. As shown in Table II, 94 micro-organisms were found responsible for SSI. 6 
Fourteen SSI were polymicrobial. 7 
Twenty-two SSI due to S. aureus were documented; 13 of these patients were classified as 8 
nasal non carriers and 9 as nasal carrier.  9 
Within the strains isolated from the 13 patients classified as nasal non carriers, 8 were 10 
available for typing by PFGE. All of these strains exhibited independent profiles (data not 11 
shown). The 5 remaining strains were isolated from patients hospitalized in 5 different 12 
centres, excluding cross transmission.  13 
In patients classified as nasal carriers, the 9 couples of strains isolated from SSI and nasal 14 
specimen were compared according to their genotype (4 cases) and/or their antimicrobial 15 
susceptibility (5 cases). From the 4 pairs of strains compared by PFGE, 2 pairs exhibited 16 
different profiles whereas 2 other pairs were shown to share a similar profile according to 17 
Tenover’s criteria (Figure 2). All of these strains were different from those isolated from 18 
infected patients classified as non carriers (data not shown). For the 5 remaining cases, nasal 19 
samples were not available for typing in 2 cases and, in 3 cases, strains recovered from the 20 
surgical site were not stored because isolated in laboratories located outside an university 21 
hospital; when compared according to antibiotypes, one of these 5 pairs was classified 22 
different whereas the four others were classified similar because of identical or minor 23 
differences in antimicrobial susceptibility (see footnotes of Table III for details).  24 
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 10 
Overall, by combining the results of genotypic and phenotypic typing methods, from a total of 1 
22 S. aureus SSI, no S. aureus nasal carriage was noted in 13 patients; in the 9 remaining 2 
patients, 3 pairs of strains were different and 6 pairs were similar (Table III). So, with the 3 
hypothesis of maximum bias, at least 16 of the 22 cases of S. aureus SSI were independent of 4 
nasal carriage of S. aureus at the time of surgery. 5 
 6 
SSI and nasal carriage 7 
S. aureus was isolated in the nose of 790 patients at the time of surgery (20.2%). Methicillin 8 
resistant S. aureus (MRSA) strains were isolated in only 0.6% of patients. The overall risk of 9 
SSI was measured at 2% (CI 95% [1.6 – 2.4], range 0 – 7.6 according to the centre). The 10 
prevalence of SSI due to S. aureus was 0.6 % (CI 95% [0.36 – 0.84]).  11 
 12 
Risk factors for SSI 13 
Univariate and multivariate analyses were performed to assess the risk factors for SSI (Table 14 
IV). In multivariate analysis, significant risk factors were tobacco use, wound haematoma and 15 
NNIS score for the occurrence of SSI., nasal carriage together with tobacco use and NNIS 16 
score for SSI due to S. aureus (Table IV). 17 
 18 
 19 
Discussion 20 
 21 
The present study is, to our knowledge, the largest evaluation of nasal carriage of S. aureus in 22 
patients undergoing orthopaedic surgery.  It confirms that nasal carriage of S. aureus at the 23 
time of surgery is a risk factor for S. aureus SSI in orthopaedic surgery. However 13 out of 22 24 
S. aureus SSI occurred in non carriers, and the majority (16/22) of S. aureus SSI were 25 
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 11 
independent of nasal carriage, suggesting an exogenous pathway of contamination.  Recently, 1 
two studies performed in cardiothoracic surgery [19] and in general surgery [20] showed that 2 
endogenous nasal contamination was the major acquisition pathway for methicillin-3 
susceptible S. aureus (MSSA), whereas exogenous acquisition pathway was essential for 4 
methicillin-resistant S. aureus (MRSA), underscoring the crucial role of hospital infection 5 
control measures.  6 
Several criticisms can be addressed to our study. First, we have limited the sampling to the 7 
anterior nares since this site is considered to be the primary colonization site of S. aureus [21, 8 
22].  Recently [23], a large study has highlighted the importance of the throat as a significant 9 
site of S. aureus carriage, with an additional sensitivity of 25.7% when combined to nasal 10 
sampling. It confirmed, however, that the anterior nares are the most colonized site with S. 11 
aureus. Our protocol included initially a rectal swabbing before surgery; however, since many 12 
patients denied this sample, the data regarding rectal specimens could not be taken into 13 
consideration. With a single nasal sample and in the absence of additional throat and rectal 14 
specimens, the frequency of carriage of S. aureus in our cohort was certainly underestimated, 15 
as illustrated by the figure of 20.2% of nasal carriers in this study compared to 37.1% in the 16 
one of Mertz et al [23] that combined nasal and throat samplings. Second, we obtained only 17 
one qualitative (and not quantitative) nasal sample from each patient. However, the most 18 
predictive factor for S. aureus infections is the persistent carriage pattern [24]. Getting up to 19 
seven nasal swab cultures to accurately segregate non-carriers from intermittent carriers, as 20 
suggested by Nouwen et al. [25], was not practically feasible for such a large effective. 21 
Indeed, most S. aureus screening programs require only one swabbing of the anterior nares [8, 22 
13, 15]. Third, with an end-point at 1 year after the device implantation, we missed late 23 
infections (> 2 years) [26].  However, the latter infections are not systematically attributed to a 24 
per-operative contamination and are mostly caused by organisms other than S. aureus [4].   25 
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 12 
Fourth, and this is the major weakness of our study, many strains of S. aureus were not 1 
available for molecular typing because infection was often detected outside the surgical 2 
setting and the corresponding laboratory omitted to keep the strain.  3 
Despite these criticisms, in our study, with the hypothesis of maximum bias, at least 16 of the 4 
22 cases of  S. aureus SSI were not related to S. aureus nasal carriage before surgery. The 5 
origin of S. aureus may be another site of carriage, such as throat [23], perineum or digestive 6 
tract [27, 28].  Indeed, throat or intestinal carriage without nasal carriage occurs relatively 7 
frequently [23, 27],   which can provide a rationale to investigate this reservoir for 8 
endogenous origin of S. aureus infection. Orthopaedic SSI can also result from exogenous 9 
transmission, as it has been already shown, notably from the hospital environment and from 10 
health-care workers [29, 30]. It is noteworthy that, in our study, no cross transmission of S. 11 
aureus within centres was documented. Our results could explain why in general surgery [9] 12 
and in orthopaedic surgery [15], randomised controlled trials with mupirocin, eliminating 13 
solely the nasal carriage, were unable to reduce S. aureus SSI.  Concerning the strategies to 14 
prevent SSI, in the more recent SHEA/IDSA practice recommendations, the routine screening 15 
for S. aureus carriage or attempts to decolonize surgical patients with an antistaphylococcal 16 
agent in the preoperative setting remains unsolved issues [31].  17 
In conclusion, nasal carriage of  S. aureus at the time of surgery, as investigated in this study, 18 
is a risk factor for S. aureus SSI in orthopaedic surgery. However, screening for S. aureus of 19 
the nares only, did not reliably predict S. aureus SSI. In most cases of S. aureus SSI, either an 20 
endogenous origin could not be demonstrated, or pre-operative nasal colonisation retrieved a 21 
strain different from the infecting pathogen. Further studies are necessary to elucidate the role 22 
of extra-nasal S. aureus carriage and the potential role of exogenous sources of contamination 23 
in elective orthopaedic surgery. As pointed out by our results, non S. aureus nasal carriers 24 
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must also be taken into account arguing for the importance of implementing robust standard 1 
prevention strategies for SSI.  2 
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Legends of figures:  1 
 2 
Figure 1: Frequency of surgical site infection according to the type of prosthesis implemented  3 
 4 
Figure 2: SmaI PFGE profiles of strains of S. aureus isolated from four patients for whom the 5 
nasal isolate(s) and the surgical site isolate(s) were available. Strain of S. aureus NTCC 8322 6 
was used as a size marker. * indicates the reference size marker, N : nasal strain, I : isolate 7 
from SSI, S : isolate from stools 8 
 9 
 10 
  11 
 12 
 13 
 14 
 15 
 1 
Table I: Main characteristics of the 3908 patients included in the study according to the type 1 
of osteosynthetic surgery 2 
 3 
 4 
Type of osteosynthetic surgery Hip prosthesis Knee 
prosthesis 
Uni 
compartmental   
knee prosthesis 
Others Total 
Number of patients (%) 
Mean age (+/- SD) 
2321 (59.4%) 
67.7 (+/-10.8) 
1162 (29.7%) 
72.9 (+/-7.9) 
292 (7.5%) 
72.7 (+/-7.2) 
133 (3.4%) 
76.6 (+/-10.3) 
3908 (100%) 
69.9(+/- 10.0) 
Male (%) 1121 (48.3%) 408 (35.1%) 91 (31.2%) 58 (43.0%) 1678 (43.0%) 
Diabetes (%) 211 (9.0%) 159 (13.7%) 37 (12.7%) 13 (9.6%) 420 (10.7%) 
Immunocompromised patients
a 
5 (0.2%) 5 (0.4%) 1 (0.3%) 0 (0%) 11 (0.3%) 
Cigarette use 445 (19.2%) 152 (12.9%) 28 (9.6%) 17 (12.6%) 642 (16.4%) 
Rheumatoid polyarthritis 50 (2.1%) 31 (2.7%) 2 (0.7%) 7 (5.2%) 90 (2.3%) 
Antibiotic use one month prior 97 (4.2%) 49 (4.2%) 10 (3.4%) 8 (5.9%) 164 (4.2%) 
Corticosteroids use 75 (3.2%) 35 (3.0%) 6 (2.1%) 6 (4.4%) 122 (3.1%) 
Cancer 227 (9.8%) 130 (11.2%) 35 (12.0%) 16 (11.9%) 408 (10.4%) 
Renal disease 8 (0.3%) 2 (0.2%) 0 (0%) 0 (0 %) 10 (0.3%) 
Bacteriuria 50 (2.2%) 23 (2.0%) 4 (1.4%) 3 (2.2 %) 80 (2.1%) 
Blood transfusion 182 (7.8%) 156 (13.4%) 1 (0.3%) 24 (17.8%) 363 (9.3%) 
Notable hematoma 28 (1.2%) 16 (1.4%) 4 (1.4%) 0 (0%) 48 (1.2%) 
Antimicrobial prophylaxis 2310 (99.5%) 1159 (99.7%) 292 (100%) 133 (100 %) 3895 (99.7%) 
Cement use for prosthesis 
1- cement 
2 – partially cemented 
3 – no cement 
 
58 (2.5%) 
248 (10.7%) 
2017 (86.8%) 
 
418 (36.0%) 
359 (30.9%) 
384 (33.0%) 
 
25 (8.6%) 
7 (2.4%) 
260 (89.0 %) 
 
47 (33.8%) 
9 (6.8%) 
76 (57.1%) 
 
548 (14.0%) 
623 (16.0%) 
2737 (70.0%) 
Primo implementation  2254 (97.1%) 1134 (97.6%) 288 (98.6%) 13 (9.6%) 3689 (94.4%) 
SSI frequency 2.2%  1.7%  0.7% 3.8% 2.0%  
SSI frequency according to 
NNIS index 
                0 
1 
                2 
 
 
1.5% 
3.8% 
4.9% 
 
 
0.9% 
3.3% 
5.6% 
 
 
1.0% 
0% 
0% 
 
 
2.2% 
5.3% 
20.0% 
 
 
1.3% 
3.3% 
6.6% 
Frequency of SSI due to S. 
aureus 
0.8%  0.2%  0%  2.3%  0.6%  
Frequency of SSI due to S. 
aureus  according to NNIS 
index        0 
                 1 
                 2 
 
 
0.3% 
2.0% 
1.6% 
 
 
0.1% 
0.3% 
0% 
 
 
0% 
0% 
0% 
 
 
2.3% 
0% 
20.0% 
 
 
0.3% 
1.3% 
1.9% 
 5 
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a
 Immunocompromised patients: malignancy, transplantation, immunosuppressive therapy, HIV infection 7 
 8 
 9 
 10 
Table
 2 
Table II:  Microbiological data 
Bacterium Number 
Coagulase negative Staphylococcus spp.                   
Methicillin susceptible  S. aureus    
Methicillin resistant S. aureus                                                                
Enterobacteriacae                                                      
Enterococcus spp.                                                        
Streptococcus spp.                                                       
Propionibacterium acnes                                            
Pseudomonas aeruginosa                                           
Corynebacterium spp.                                                  
Pseudomonas paucimobilis                                          
Clostridium perfringens                                               
Fusobacterium spp.                                                     
Peptostreptococcus spp.                                              
Acinetobacter spp.   
Including  polymicrobial infections                                                
36 
18 
4
11 
7 
6 
3 
2 
2 
1 
1 
1 
1 
1 
14 
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Table III: Detailed results of the 22 cases of SSI due to S. aureus and their relationship with 
nasal carriage. 
 
Patient 
Type of 
surgery 
No. of days 
between 
surgery 
and SSI 
Bacterial strain 
responsible for 
SSI
a
 
 
Nasal 
sampling 
before 
surgery
a 
 
Other nasal 
samplings
a
 
 
Classification of 
pairs of S. aureus 
isolated from the 
nose and the SSI 
 
1 
Hip 
prosthesis 
15 MSSA (I4) Positive (N3)  
different (PFGE 
and AP) 
2 
Knee 
prosthesis 
15 MSSA Negative   
3 
Hip 
prosthesis 
26 MRSA  Positive  
positive one month 
after SSI diagnosis  
similar (AP)
b
 
4 
Hip 
prosthesis 
22 MSSA Negative   
5 
Hip 
prosthesis 
25 MSSA Positive 
positive 2 months 
after SSI diagnosis 
different (AP)
c
 
6 
Hip 
prosthesis 
25 MSSA  Negative  
positive at the time of 
SSI diagnosis 
 
7 
Hip 
prosthesis 
30 MSSA Negative   
8 
Hip 
prosthesis 
20 MRSA Negative   
9 
Partial hip 
prosthesis 
replacement  
24 MSSA Negative   
10 
Hip 
prosthesis 
19 MSSA Negative   
11 
Hip 
prosthesis 
22 MSSA Positive 
positive 2 months 
after SSI diagnosis 
similar (AP)
d
 
12 
Hip 
prosthesis 
43 MSSA (I9) Positive (N8) 
nose sampling 
number 2 positive 
similar (PFGE and 
AP) 
13 
Hip 
prosthesis 
35 MSSA Negative   
14 
Hip 
prosthesis 
20 MSSA Negative   
15 
Hip 
prosthesis 
23 MSSA (I2) Positive (N1)  
similar (PFGE and 
AP) 
16 
Hip 
prosthesis 
62 MSSA Negative 2 negative samplings  
17 
Knee 
prosthesis 
replacement 
82 MRSA Negative   
18 
Knee 
prosthesis 
41 MSSA Positive 
positive 13 days after 
SSI diagnosis 
similar (AP)
e
 
19 
Hip 
prosthesis 
42 MSSA Positive 
negative 2 months 
after SSI diagnosis 
similar (AP)
f
 
20 
Hip 
prosthesis 
73 MSSA Negative   
21 
Hip 
prosthesis 
41 
MSSA  
+ Klebsiella 
pneumoniae 
Negative   
22 
Hip 
prosthesis 
63 
MRSA (I7) 
+ Pseudomonas 
aeruginosa 
Positive 
(MSSA) 
(N5) 
positive MRSA (S6) 
in stools five 
days before SSI  
Different (PFGE 
and AP) 
 
SSI = surgical site infection; AP = antimicrobial profile; MSSA = Methicillin susceptible S. aureus; MRSA = 
Methicillin resistant S. aureus ; PFGE = Pulsed Field Gel Electrophoresis. 
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a 
Figures in brackets correspond to the numbering of S. aureus isolates in  Fig. 2 
b
 patient 3 harbored nasal and SSI MRSA strains that were both sensitive to all aminoglycosides but resistant to 
erythromycin and lincomycin. 
c
 patient 5 harbored distinct S. aureus strains: the nasal strain was only resistant to penicillin G and intermediate 
to norfloxacin whereas the SSI strain was resistant to penicillin G and erythromycin and sensitive to norfloxacin. 
d
 patient 11 harbored nasal and SSI MSSA strains that were both sensitive to all tested antibiotics except 
penicillin G. 
e
 patient 18 harbored nasal and SSI MSSA strains both only resistant to penicillin G. 
f
 patient 19 Nasal strain was only resistant to penicillin G although the SSI strain was resistant to penicillin G 
and intermediate to pristinamycin 
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Table IV: Univariate and multivariate analysis of risk factors for SSI overall and SSI due to 
S. aureus 
 
 
 
Risks factors Univariate analysis Multivariate analysis 
For SSI overall P P Exp (B) CI 95%  
    
Centre  < 0.01 0.0379 Adjustment factor 
Age 0.03   
BMI < 0.001   
Tobacco use 0.003 0.0018 2.244 [1.352 - 3.726] 
Diabetes 0.04   
Cancer 0.06   
Corticosteroids 0.1   
First implantation 0.07   
Duration of surgery  0.004   
Hematoma 0.002 0.0026 4.665 [1.714 - 12.695] 
Nasal carriage of S. aureus 0.3   
NNIS < 0.001 < 0.0001 3.073 [1.874 - 5.038] 
ASA score > 2 < 0.01   
    
For SSI due to S.aureus 
 
Centre 
 
 
NS 
 
 
0.9978 
 
 
Adjustment factor 
ASA score > 2 < 0.01   
BMI 0.2   
Tobacco use 0.005 0.0024 3.907 [1.621 - 9.420] 
Diabetes 0.025   
Cancer 0.02   
Duration of surgery 0.02   
Nasal carriage of S. aureus 0.02 0.0208 2.786 [1.169 - 6.640] 
NNIS < 0.001 0.0007 5.205 [2.013 - 13.455] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Dear Editor, 
 
Please find enclosed a revised manuscript of our study entitled “Is nasal carriage of 
Staphylococcus aureus the main acquisition pathway for surgical-site infection in orthopaedic 
surgery?” Ms. No. EJCMID-D-09-00479 and the answers, point by point, to the queries of the 
two reviewers that are detailed below. The main changes done are highlighted in yellow in 
one of the copy of the new manuscript. 
 
We hope that this new version will be found suitable for publication in your journal.  
I look forward to hearing from you soon. 
Sincerely yours, 
 
Pr Berthelot 
MD, PhD. 
 
 
Reply to reviewers 
 
Thank you for these interesting comments. Please find below our answers to the queries of the 
two reviewers. 
 
 
Reviewer 1 
 
It is unfortunate that they did not screen other sites such as the throat 
and perineum. 
 
We agree with this comment. Initially, the protocol included a rectal swabbing but many 
patients were reluctant to this proposal. Due to a high rate of missing data during the initial 
step of the study, we decided to stop the sampling of this site. The following sentence was 
added in the discussion section of the new manuscript (page 11; lines 12 to 14): “Our protocol 
included initially a rectal swabbing before surgery; however, since many patients denied this 
sample, the data regarding rectal specimens could not be taken into consideration”. 
Concerning the throat sampling, when the study was designed in 2002, sampling this site was 
not recommended since this specimen was not considered at this time to increase significantly 
the sensitivity of the recovery of S. aureus from the upper respiratory tract as shown later by 
Metz et al. in 2007 [ref 23] (this point is discussed page 11, lines 14 to 17). 
 
 
They could point out that sole carriage at these sites is rare (perhaps 
10%) and add this to their estimates of the possible size of the problem 
(20% larger!). Nasal carriage rather than carriage should be in the text. 
 
We also agree with this comment, which is emphasised in the new discussion section (page 
11; lines 14 to 17): “With a single nasal sample and in the absence of additional throat and 
rectal specimens, the frequency of carriage of S. aureus in our cohort was certainly 
underestimated, as illustrated by the figure of 20.2% of nasal carriers in this study compared 
to 37.1% in the one of Mertz et al [23] that combined nasal and throat samplings.” 
 
 
Authors' Response to Reviewers' Comments
Click here to download Authors' Response to Reviewers' Comments: Reply to reviewers9nov09.doc
Comment 1 about CNS data: 
1) Table 3 has overall data.  They could compare the antibiograms of the 
individual isolates and see if there are very different strains.  I doubt 
the organisms are available for molecular analysis (if so this could be 
"future work" for the discussion) but at least the antibiograms could be 
compared by ward and centre and see if there are any similarities and 
differences and informed guesses made as to the likelihood of cross 
infection e.g. quinolone resistance is  usually mutational 
2) All the other infected organism data.  Again what about antibiograms and 
possible cross infection? 
 
The goal of the study was to address the potential link between S. aureus nasal carriage and 
occurrence of S. aureus SSI, and not to study CNS or other bacterial cross infections. Strains 
other than S. aureus were not kept for further analysis. By contrast, the potentiality of cross 
infections with S. aureus was investigated and presented with some details in the revised 
manuscript (see below). 
 
 
3) S aureus data. 
We need to see their rule set for deciding why the extra 5 strains were 
different or similar. This is a difficult area and must be explained. 
 
The way used to compare antibiotypes is reported in the method section (page 6, lines 12 to 
16). As required by the referee, additional information regarding the comparison of antibiotic 
profiles has been added in the footnotes of Table III. 
 
 
They should compare the 13 SA from non carriers (and indeed the carriers) 
to see if there are possible issues of cross infection in terms of time 
person and place of the affected patients.  Are these strains similar by 
PFGE?  Are they similar to any of the carriers? 
 
From the 13 S. aureus SSI strains isolated from non nasal carriers, 8 were available for 
comparison by PFGE: all these strains exhibited independent profiles, also different from 
those of strains isolated from the nose of colonised patients. The 5 remaining strains were 
isolated from non nasal carriers hospitalized in 5 different centres, excluding cross 
transmission. These data were added in the result section page 9 lines 10 to 13. 
 
 
Table IV only has death related risk analysis not as stated on page 10 
lines 23-24 for SSI and SA nasal carriage. 
 
Because of the low number of SSI infections, the multivariate analysis was run with a 
maximum of 3 covariates selected among the most significant in the univariate analyses. This 
sentence was added in the method section (page 8 lines 8 to 10). We also modified the 
sentence presenting Table IV (page 10 lines 14 to 15). 
 
 
4) There are also the therapeutic issues raised by the AST results for all 
categories of infections above.  These are perhaps a little peripheral but 
I think it would add to the paper or perhaps be another one if there are 
clinical outcome data? 
 
Data regarding therapeutic issues are not presented in this paper. Another clinical paper 
focusing on these results is in preparation 
 
 
Other points 
How were nasal swabs taken: were the swabs moistened? 
 
The precision regarding moistened transport medium was added in the method section (page 
5, line 1). 
 
 
Was the PFGE protocol validated to be able to distinguish strains and how?  
 
The criteria for PFGE interpretation are described page 6 lines 10 to 12 “For a same patient, 
according to Tenover’s criteria [18], two S. aureus strains were classified as 
epidemiologically distinct if a difference of more than three bands was ascertained between 
the PFGE profiles performed in a same run”. 
 
 
Reviewer 2 
 
First this was a multicenter study and in these kind of studies cluster 
effects may occur. In the multivariate analysis, adjustment for cluster 
effects was not included. This would strengthen the conclusions. 
 
As pointed by the reviewer it is important to look for cluster effect. This was investigated by 
adding a “centre” variable in the different statistical analyses. This variable did not remain in 
the final model used for multivariate analysis. But as required by the referee, we performed 
another multivariate analysis using windows SAS® 9.1 software to adjust for cluster effect. 
This was added in the method section (page 7, line 25). We replaced the results of the 
previous multivariate analysis performed using SPSS software by the results of this 
multivariate analysis adjusted for cluster effect (Table IV). 
 
 
Second, the authors conclude that the majority of the S. aureus strains are 
of exogenous origin. They put it quite strong in the conclusions that 'at 
least 16 were not endogenous'. In my opinion this is not correct. The nasal 
cultures were negative but this may have been a false-negative result, e.g. 
due to the sampling technique. As the carriage rate was only 20% it is 
clear that the culture technique was not very sensitive (normally 30% of 
the population is nasal carrier). Therefore, I suggest to modify this 
conclusion.  
In the majority of cases an endogenous origin could not be demonstrated 
would be more correct.  
 
We agree with this comment. The discussion section was amended accordingly (see answer to 
reviewer 1 and additional sentence in page 11; lines 14 to 17)). 
As suggested by the referee, we also modified the conclusion; the sentence “In most cases of 
S. aureus SSI, pre-operative nasal colonization was not documented or retrieved a different 
strain from the infecting pathogen” was replaced by the following one in the new manuscript 
(page 12, lines 20 to 22 and in the abstract): “In most cases of S. aureus SSI, either an 
endogenous origin could not be demonstrated, or pre-operative nasal colonisation retrieved a 
strain different from the one recovered from the surgical site” 
 
 
Also, it would be important to provide information on the typing of the 
strains from non-carriers as well. I wonder whether there were many similar 
strains within centers suggesting a common source? 
 
This point was also addressed by reviewer 1. No cross transmission of S. aureus was 
documented in this cohort. This important point was added in the result and discussion 
section, page 9 lines 10 to 13. The following sentence was added page 12 line 11 to 12 “It is 
noteworthy that, in our study, no cross transmission of S. aureus within centres was 
documented”. 
